pHAGE-PIK3CA-E545K Citations (2)

Originally described in: Systematic Functional Annotation of Somatic Mutations in Cancer.
Ng PK, Li J, Jeong KJ, Shao S, Chen H, Tsang YH, Sengupta S, Wang Z, Bhavana VH, Tran R, Soewito S, Minussi DC, Moreno D, Kong K, Dogruluk T, Lu H, Gao J, Tokheim C, Zhou DC, Johnson AM, Zeng J, Ip CKM, Ju Z, Wester M, Yu S, Li Y, Vellano CP, Schultz N, Karchin R, Ding L, Lu Y, Cheung LWT, Chen K, Shaw KR, Meric-Bernstam F, Scott KL, Yi S, Sahni N, Liang H, Mills GB Cancer Cell. 2018 Mar 12;33(3):450-462.e10. doi: 10.1016/j.ccell.2018.01.021. PubMed Journal

---

Articles Citing pHAGE-PIK3CA-E545K

Articles
PAK and PI3K pathway activation confers resistance to KRAS(G12C) inhibitor sotorasib. Chan CH, Chiou LW, Lee TY, Liu YR, Hsieh TH, Yang CY, Jeng YM. Br J Cancer. 2023 Jan;128(1):148-159. doi: 10.1038/s41416-022-02032-w. Epub 2022 Nov 1. PubMed
Microphysiological model of PIK3CA-driven vascular malformations reveals a role of dysregulated Rac1 and mTORC1/2 in lesion formation. Aw WY, Cho C, Wang H, Cooper AH, Doherty EL, Rocco D, Huang SA, Kubik S, Whitworth CP, Armstrong R, Hickey AJ, Griffith B, Kutys ML, Blatt J, Polacheck WJ. Sci Adv. 2023 Feb 15;9(7):eade8939. doi: 10.1126/sciadv.ade8939. Epub 2023 Feb 15. PubMed

If you have published an article using this material, please email us at to have your article added to this page.